Trials / Completed
CompletedNCT02641067
A Study Evaluating the Pharmacokinetics of Doravirine (MK-1439) in Participants With Severe Renal Impairment (MK-1439-051)
An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MK-1439 (Doravirine) in Subjects With Severe Renal Impairment
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
This study will evaluate the effect of severe renal impairment on the pharmacokinetics of doravirine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Doravirine | Following an overnight fast, a single coated tablet of 100 mg doravirine will be administered orally |
Timeline
- Start date
- 2016-01-26
- Primary completion
- 2016-05-14
- Completion
- 2016-05-25
- First posted
- 2015-12-29
- Last updated
- 2019-02-08
- Results posted
- 2019-02-08
Source: ClinicalTrials.gov record NCT02641067. Inclusion in this directory is not an endorsement.